| Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635) |
|---|
| 04/03/2003 | WO2002070559A3 Nuclear hormone receptor ligand binding domains |
| 04/03/2003 | WO2002030404A3 Combination therapy for premenstrual symptoms |
| 04/03/2003 | WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents |
| 04/03/2003 | WO2002014369A9 Human kininogen d5 domain polypeptides and their use |
| 04/03/2003 | WO2002000860A3 Novel proteases |
| 04/03/2003 | US20030065195 Ether compounds |
| 04/03/2003 | US20030065174 Antiinflammatory agents; analgesics |
| 04/03/2003 | US20030065023 Anticancer agents, viricides, psychological disorders |
| 04/03/2003 | US20030065017 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists / antagonists, estrogens and progestins |
| 04/03/2003 | US20030065007 Analgesics; psychological disorders; antidepressants |
| 04/03/2003 | US20030065004 Androgen receptor modulators and methods for use thereof |
| 04/03/2003 | US20030064973 Sexual disorders |
| 04/03/2003 | US20030064938 Cardiovascular disorders; menstraution disorders; anticancer agents |
| 04/03/2003 | US20030064919 Novel polypeptides and polynucleotides encoding same |
| 04/03/2003 | US20030064114 For vasodilatation and inhibition of transplant rejection |
| 04/03/2003 | US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/03/2003 | US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents |
| 04/03/2003 | US20030064052 Useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery |
| 04/03/2003 | CA2688860A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 04/03/2003 | CA2461709A1 Small organic molecule regulators of cell proliferation |
| 04/03/2003 | CA2461363A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| 04/03/2003 | CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| 04/03/2003 | CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity |
| 04/03/2003 | CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity |
| 04/03/2003 | CA2461140A1 Inactivation of papillomavirus |
| 04/03/2003 | CA2461095A1 Process for making substituted pyrazoles |
| 04/03/2003 | CA2460953A1 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | CA2459943A1 Androstanes as androgen receptor modulators |
| 04/03/2003 | CA2458661A1 Methods of increasing endogenous testosterone levels |
| 04/03/2003 | CA2446904A1 Delivery of drug esters through an inhalation route |
| 04/02/2003 | EP1298348A1 Bush, group of bush, suspension cross-member, vehicle, method for mounting a bush and method for mounting a group of bushes |
| 04/02/2003 | EP1298211A2 Polynucleotide segment of HPV16 Genome |
| 04/02/2003 | EP1298206A1 Use of the Factor VII-activating protease for prevention and therapy of vaso-proliferative disorders |
| 04/02/2003 | EP1297848A1 Preventives/remedies for granuloma |
| 04/02/2003 | EP1297136A2 Full length human hcn1 ih channel subunit and variants |
| 04/02/2003 | EP1297017A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 04/02/2003 | EP1297014A2 Transporters and ion channels |
| 04/02/2003 | EP1296996A1 Purine derivatives |
| 04/02/2003 | EP1296990A2 Dihydropyridine compounds for the inhibition of calcium-influx |
| 04/02/2003 | EP1296986A1 5-aminoalkyl-pyrazolo 4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect |
| 04/02/2003 | EP1296983A1 Novel process for the preparation of pyrazolopyrimidinones |
| 04/02/2003 | EP1296981A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 04/02/2003 | EP1296976A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 04/02/2003 | EP1296956A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors |
| 04/02/2003 | EP1296951A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 04/02/2003 | EP1296943A1 Amino acid derivatives and their use as medicines |
| 04/02/2003 | EP1296938A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| 04/02/2003 | EP1296929A2 Modified forms of pharmacologically active agents and uses therefor |
| 04/02/2003 | EP1296693A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
| 04/02/2003 | EP1296691A2 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 04/02/2003 | EP1296687A2 Treatment of male sexual dysfunction |
| 04/02/2003 | EP1296686A2 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora |
| 04/02/2003 | EP1296679A1 Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
| 04/02/2003 | EP1296670A1 Therapeutic combinations of fatty acids |
| 04/02/2003 | EP1296644A2 Systems and methods for treating a mucosal surface |
| 04/02/2003 | EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 04/02/2003 | EP1212312B1 Novel derivatives of flavones, xanthones and coumarins |
| 04/02/2003 | EP1208100B1 Selective antagonists of a2b adenosine receptors |
| 04/02/2003 | EP1121108B1 Novel therapeutic use of compounds with beta-3-agonist activity |
| 04/02/2003 | EP1043993B1 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents |
| 04/02/2003 | CN1407986A Novel imidazotriazinones and the use thereof |
| 04/02/2003 | CN1407984A 1,8-naphthyridin-2 (1H)-one derivatives |
| 04/02/2003 | CN1407971A Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 04/02/2003 | CN1407898A Novel topical oestroprogestational compositions with systemic effect |
| 04/02/2003 | CN1407896A Exemestane for first-line treatment of breast cancer |
| 04/02/2003 | CN1407895A Pharmaceutical combination of ethinylestradiol and drospirenone for use as contraceptive |
| 04/02/2003 | CN1406606A Preparation for treating blood stasis in woman pelvic cavity |
| 04/02/2003 | CN1406523A Oral liquid production |
| 04/02/2003 | CN1104440C Method for variation of chromatin condensation |
| 04/02/2003 | CN1104432C Pyrrole triazines and pyrimidine compound |
| 04/02/2003 | CN1104421C Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
| 04/02/2003 | CN1104418C Benzoheterocyclic derivatives |
| 04/02/2003 | CN1104247C Suppository for treating cervical erosion and vaginitis |
| 04/01/2003 | US6541669 Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis |
| 04/01/2003 | US6541638 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction |
| 04/01/2003 | US6541623 Sepsis shock therapy; rheumatic diseases; antiinflammatory agents; nucleotide sequence detector |
| 04/01/2003 | US6541487 Administering 5-bromoquinoline, 5-nitroisoquinoline, 8-nitroisoquinoline, 3,4-dihydro-6-hydroxy-2(1H)-quinolone or 1-methylisoquinoline to relax corpus cavernosa smooth-muscle tissue in males or females |
| 04/01/2003 | US6541465 Orally active androgens |
| 04/01/2003 | US6541463 Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use |
| 04/01/2003 | US6540980 Method of detecting endometriosis |
| 04/01/2003 | CA2102129C Growth hormone antagonists |
| 03/28/2003 | CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue |
| 03/28/2003 | CA2404045A1 Use of coagulation factor vii-activating protease for the prophylaxis and therapy of vasoproliferative disorders |
| 03/27/2003 | WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 03/27/2003 | WO2003025131A2 Protein modification and maintenance molecules |
| 03/27/2003 | WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity |
| 03/27/2003 | WO2003024922A1 Hydroxyfattysulfonic acid analogs |
| 03/27/2003 | WO2003024465A2 Use of extracts of the genus cimicifuga as organoselective medicines |
| 03/27/2003 | WO2003024459A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 03/27/2003 | WO2003024440A1 Salicylic acid salts, methods for the production and use thereof as medicaments |
| 03/27/2003 | WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 03/27/2003 | WO2003024438A1 Composition comprising cysteamine for improving lactation in dairy animals |
| 03/27/2003 | WO2003024402A2 Lpa receptor agonists and antagonists and methods of use |
| 03/27/2003 | WO2003024395A2 Linked biaryl compounds |
| 03/27/2003 | WO2003024390A2 Hydroxyeicosenoic acid analogs |
| 03/27/2003 | WO2003002058A8 Bone anabolic compounds and methods of use |
| 03/27/2003 | WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 03/27/2003 | WO2002083870A3 Pufa polyketide synthase systems and uses thereof |
| 03/27/2003 | WO2002026774A3 Melanocortin receptor ligands |
| 03/27/2003 | WO2002019999A3 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant |